Iovance Biotherapeutics, Inc.IOVANASDAQ
Loading
Year-over-year research & development expense growth
Percentile
P15
Within normal range
vs 5Y Ago
-0.4x
Contraction
Streak
3 qtr
Consecutive declineDecelerating
| Period | Value |
|---|---|
| Q4 2025 | -8.41% |
| Q3 2025 | -5.28% |
| Q2 2025 | 3.23% |
| Q1 2025 | 6.45% |
| Q4 2024 | 5.83% |
| Q3 2024 | 9.92% |
| Q2 2024 | -22.18% |
| Q1 2024 | -8.79% |
| Q4 2023 | -0.06% |
| Q3 2023 | 1.37% |
| Q2 2023 | 4.37% |
| Q1 2023 | 2.68% |
| Q4 2022 | 11.13% |
| Q3 2022 | -1.23% |
| Q2 2022 | 7.48% |
| Q1 2022 | -9.68% |
| Q4 2021 | 15.70% |
| Q3 2021 | 5.21% |
| Q2 2021 | 11.03% |
| Q1 2021 | 6.67% |
| Q4 2020 | 21.84% |
| Q3 2020 | -12.63% |
| Q2 2020 | -13.48% |
| Q1 2020 | 5.00% |
| Q4 2019 | 30.44% |
| Q3 2019 | 5.81% |
| Q2 2019 | 27.16% |
| Q1 2019 | 12.72% |
| Q4 2018 | -1.89% |
| Q3 2018 | 13.83% |
| Q2 2018 | 23.30% |
| Q1 2018 | -3.79% |
| Q4 2017 | 16.58% |
| Q3 2017 | -9.67% |
| Q2 2017 | 18.23% |
| Q1 2017 | 70.65% |
| Q4 2016 | 14.86% |
| Q3 2016 | 90.03% |
| Q2 2016 | 6.46% |
| Q1 2016 | -5.16% |